Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI (NASDAQ: ...

Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.

Tempus AI, Inc. Class A (($TEM)) has held its Q2 earnings call. Read on for the main highlights of the call. Tempus AI, Inc. Class A recently held ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...